An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
about
Micelle-Based Adjuvants for Subunit Vaccine DeliveryVaccine Adjuvants: from 1920 to 2015 and BeyondB Cells and Functional Antibody Responses to Combat InfluenzaSafety assessment of adjuvanted vaccines: Methodological considerationsSafety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic reviewDevelopment of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical SynthesisSynthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responsesIdentification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines.A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresisAn update on the use of laser technology in skin vaccination.Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.Particle-based platforms for malaria vaccines.Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activityAdditive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations.Old and new adjuvants for hepatitis B vaccines.Vaccine technologies: From whole organisms to rationally designed protein assemblies.Donor-unrestricted T cells in the human CD1 system.Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants.Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.Diatoms and diatomaceous earth as novel poultry vaccine adjuvants.Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.Vaccine adjuvants.Are we entering a new age for human vaccine adjuvants?A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation.Intravitreal injection of polysorbate 80: a functional and morphological study.Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.Manufacture of Oil-in-Water Emulsion Adjuvants.AS03 stresses out macrophages: Commentary on ‘Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties’.Prospects on the Use of sp. to Develop Oral Vaccines
P2860
Q26783010-522EFD2F-F347-4F7F-BF3B-B04000223482Q26783879-E07D6917-3F6B-4193-BD57-542581AB1E33Q26801639-1CD4E93E-C4B2-4CE3-9CB9-05BA401BDA6BQ27013956-E8C42A79-FBCD-4089-87F1-4D540450D0B7Q28084805-F126B8F0-9BC9-4799-896D-140FC9234922Q28829361-F6FD0D19-2327-4563-AD77-C244C7DB8CF9Q30205195-BDBBAB30-075B-4C8F-9E1D-3D79F58D2A3EQ30371303-34154F87-8316-4E0C-9878-A6ED1D1A8F8BQ30372260-A17A338E-31C4-461E-B0EC-1DA40844892FQ30401247-248E5E64-ABA0-4D57-8321-3C7EFCBE4A26Q33641234-B084398E-3C0F-4017-9C6B-87AEB09EE958Q35017651-AE0A5A98-4E35-4BFA-86B6-B011D48D91BFQ35034311-120A4D42-EADA-43CE-BE4E-C9305715381EQ36396040-5A6D0099-C089-41DF-BB65-0E3B8CA91B5DQ37434381-A1471364-7C14-4690-AEA2-C523FA645A39Q37563632-92BD6BC4-C743-48EE-9944-AB0E77C44BD2Q38168915-22BF1559-EA53-47E6-A45A-4395B79E7F0BQ38293586-954FF98F-5FB5-4E3C-A5CB-1440331D29C0Q38806558-56E94010-DC64-478D-AA27-40DE075CED1BQ38922079-154EF9C4-EA82-4BCC-BF74-6CEAA500083CQ38953988-3411503C-CF07-4497-B5A7-0329E39141E6Q39726192-6ED58A36-6CDC-4F1B-9DEE-C668EA4F35FAQ40095257-F1AEF4FF-120E-420B-80FB-4D3B360F9B39Q40116011-4DF9EFF1-BC53-4C0F-BA47-A991E044EABDQ40644104-8D3BDB37-341B-496B-8FF0-783815866638Q41151191-DA213A76-7795-4EFB-A9E2-E9E3D0B20C9FQ44800976-A7B71C7A-77AD-4B93-AD71-7A1E1214EA61Q47913363-4236CCD5-B316-4756-BD12-B91D5C4CE867Q48238063-D4F7AD08-2D7D-4F91-8E66-97FC1A1A0A0FQ50135539-BA1E811B-8BBA-48BD-B843-9D87DA00F3E3Q51743232-19A9013F-EFB5-4DD6-BE6D-0FC573525FAAQ54400892-34E51289-114C-4A60-8E09-A2C86534F9A3Q55437009-343C7CF5-2510-4A14-96EF-CE877C46EFFFQ58556430-7CDAF428-C08A-482B-A961-78644A7C02F4
P2860
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
@ast
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
@en
type
label
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
@ast
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
@en
prefLabel
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
@ast
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
@en
P2860
P1476
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants
@en
P2093
Jean Haensler
P2860
P304
P356
10.1586/14760584.2013.811188
P577
2013-07-01T00:00:00Z